Radan Lea, Fischer Doron, Bar-Shalom Rachel, Dann Eldad J, Epelbaum Ron, Haim Nissim, Gaitini Diana, Israel Ora
Department of Nuclear Medicine, Rambam Health Care Campus, Haifa, Israel.
Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1424-30. doi: 10.1007/s00259-008-0771-8. Epub 2008 Apr 17.
The use of 18F-fluoro-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in primary gastric lymphoma (PGL) is challenging due to physiologic FDG activity in the stomach and variability in the degree of uptake in various histologic subtypes. This study assesses FDG avidity and PET/CT patterns in newly diagnosed PGL.
Sixty-two PET/CT studies of newly diagnosed PGL were reviewed (24 low-grade mucosa-associated lymphoid tissue [MALT], 38 aggressive non-Hodgkin's lymphoma [AGNHL]). FDG avidity, patterns (focal/diffuse), and intensity (visually vs. the liver and SUVmax) were assessed and compared to 27 controls. Gastric CT abnormalities and extragastric sites were recorded.
Gastric FDG uptake was found in 55/62 (89%) PGL (71% MALT vs. 100% AGNHL, p < 0.001) and 63% controls. A diffuse pattern was found in 60% PGL (76% MALT vs. 53% AGNHL, p = NS) and 47% controls. FDG uptake higher than liver was found in 82% PGL (58% MALT vs. 97% AGNHL, p < 0.05) and 63% controls. SUVmax in FDG-avid PGLs was 15.3 +/- 11.7 (5.4 +/- 2.9 MALT vs. 19.7 +/- 11.5 AGNHL, p < 0.001) and 4.6 +/- 1.4 in controls. CT abnormalities were found in 79% PGL (thickening, n = 49; ulcerations, n = 22). Extra-gastric FDG-avid sites were seen in none of MALT, but 61% of AGNHL (nodal, n = 18; nodal and extranodal, n = 5).
FDG avidity was present in 89% of PGLs, including all patients with AGNHL but only 71% of MALT. FDG uptake can be differentiated, in particular in AGNHL-PGL, from physiologic tracer activity by intensity but not by pattern. Extragastric foci on PET and structural CT abnormalities are additional parameters that can improve PET/CT assessment of PGL. Defining FDG avidity and PET/CT patterns in AGNHL and a subgroup of MALT-PGL before treatment may be important for further monitoring therapy response.
由于胃内生理性氟代脱氧葡萄糖(FDG)活性以及不同组织学亚型摄取程度的变异性,18F - 氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG - PET/CT)在原发性胃淋巴瘤(PGL)中的应用具有挑战性。本研究评估新诊断PGL中的FDG亲和力及PET/CT模式。
回顾了62例新诊断PGL的PET/CT研究(24例低度黏膜相关淋巴组织淋巴瘤[MALT],38例侵袭性非霍奇金淋巴瘤[AGNHL])。评估FDG亲和力、模式(局灶性/弥漫性)和强度(视觉上与肝脏比较及SUVmax),并与27例对照进行比较。记录胃部CT异常及胃外部位情况。
55/62(89%)例PGL存在胃FDG摄取(MALT为71%,AGNHL为100%,p < 0.001),对照为63%。60%例PGL呈弥漫性模式(MALT为76%,AGNHL为53%,p = 无显著性差异),对照为47%。82%例PGL的FDG摄取高于肝脏(MALT为58%,AGNHL为97%,p < 0.05),对照为63%。FDG摄取阳性的PGL的SUVmax为15.3±11.7(MALT为5.4±2.9,AGNHL为19.7±11.5,p < 0.001),对照为4.6±1.4。79%例PGL发现CT异常(增厚,49例;溃疡,22例)。MALT均未见胃外FDG摄取阳性部位,而61%例AGNHL有(淋巴结,18例;淋巴结及结外,5例)。
89%的PGL存在FDG摄取,包括所有AGNHL患者,但MALT仅71%。FDG摄取可通过强度而非模式与生理性示踪剂活性相鉴别,尤其是在AGNHL - PGL中。PET上的胃外病灶及结构性CT异常是可改善PGL的PET/CT评估的额外参数。在治疗前明确AGNHL及部分MALT - PGL中的FDG亲和力及PET/CT模式可能对进一步监测治疗反应很重要。